INSMED Inc INSM
1 target with a reported result
Releases of the last 3 yearsThe numbers INSM said it expected, in its earnings releases, next to what it then reported for the same period.
Target by target
Each target, with the sentence it came from · release and 10-Q or 10-K
| Target | What the company said | Reported | Result | |
|---|---|---|---|---|
| Revenue Fiscal 2026 |
Given at least $1.00B release Feb 19, 2026
Kept at least $1.00B release May 7, 2026
Changed $1.25B to $1.40B release Aug 6, 2026
|
– | Not reported yet | |
The company's wordsInsmed anticipates full-year 2026 BRINSUPRI revenues of at least $1 billion. release Feb 19, 2026 The Company continues to anticipate full-year 2026 BRINSUPRI revenues of at least $1 billion. release May 7, 2026 The Company raised its guidance for full-year 2026 BRINSUPRI revenues to a range of $1.25 billion to $1.40 billion from the previous guidance of release Aug 6, 2026 | ||||
| Revenue Fiscal 2024 (ended Dec 31, 2024) |
Given $340.00M to $360.00M release Feb 22, 2024
Kept $340.00M to $360.00M release May 9, 2024
Kept $340.00M to $360.00M release Aug 8, 2024
Kept $340.00M to $360.00M release Oct 31, 2024
|
$363.71M 10-K filed 2025-02-20 |
Above the range | |
The company's wordsInsmed is reiterating its sales guidance for full-year 2024 global … ARIKAYCE revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023. release Feb 22, 2024 Insmed is reiterating its sales guidance for full-year 2024 global … ARIKAYCE revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023. release May 9, 2024 Insmed is reiterating its guidance for full-year 2024 global ARIKAYCE … revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023. release Aug 8, 2024 Insmed is reiterating its guidance for full-year 2024 global ARIKAYCE … revenues in the range of $340 million to $360 million, representing 15% year-over-year growth at the midpoint compared to 2023. release Oct 31, 2024 | ||||
Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-22), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.
Sources
The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.
Also
Earnings releases: each release in full.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSM/export.csv") into a cell.